Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.
Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.
Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.
Merck (NYSE: MRK) has announced promising results from a Phase 1 study of its investigational islatravir subdermal implant for HIV-1 pre-exposure prophylaxis (PrEP). The study, presented at CROI 2021, showed active drug levels exceeding the necessary PK threshold at 12 weeks across all studied doses (48 mg, 52 mg, and 56 mg), with the 56 mg dose projected to provide effective drug levels for up to a year. Merck plans to initiate a Phase 2 trial to further assess this long-acting option for HIV prevention.
Merck and Ridgeback Biotherapeutics announced preliminary results from a Phase 2a trial evaluating molnupiravir for SARS-CoV-2 treatment. The study showed a significant reduction in days to negativity of infectious virus in participants receiving molnupiravir compared to placebo (0% vs. 24%). This multi-center trial enrolled 202 adults, and no safety signals were identified. The primary results remain blinded. Further studies are underway, with updates planned in the future. Molnupiravir is an investigational oral antiviral showing promise against various RNA viruses including SARS-CoV-2.
Merck (NYSE: MRK) has initiated a cash tender offer for all outstanding shares of Pandion Therapeutics, Inc. (Nasdaq: PAND), offering $60 per share. This acquisition aims to enhance Merck's portfolio and is expected to close in the first half of 2021, subject to specific conditions. Stockholders are encouraged to accept the offer, detailed in the tender offer statement filed with the SEC. Merck’s acquisition signifies a strategic expansion and potential revenue growth as it continues focusing on innovative therapeutics.
Merck (NYSE: MRK) announced that Michael T. Nally, chief marketing officer, will speak at the Barclays Global Healthcare Conference on March 9, 2021, at 1:50 p.m. EST. Investors, analysts, and the public are invited to watch the live video webcast through Merck's investor events page.
Merck, dedicated to advancing health through medicines and vaccines, continues to focus on combating serious diseases, including cancer and infectious diseases. For more details, visit www.merck.com.
Merck (NYSE: MRK) announced significant presentations from its HIV clinical development at CROI 2021, running virtually from March 6-10, 2021. The highlights include late-breaking Phase 1 results for islatravir, aimed at HIV treatment and prevention. Key findings discuss a new subdermal drug-eluting implant for extended islatravir administration, pharmacokinetic data for monthly oral islatravir, and updates on the DELSTRIGO regimen for adolescents. Merck emphasizes its commitment to advancing innovative strategies in HIV care.
Merck (NYSE:MRK) announced multiple agreements to boost manufacturing capacity for SARS-CoV-2/COVID-19 vaccines and medicines, receiving up to $268.8 million in funding from BARDA. This funding will support adapting existing facilities for vaccine and medicine production. Additionally, Merck will collaborate with Janssen Pharmaceuticals to produce components of its COVID-19 vaccine. Merck plans substantial capital investments exceeding $20 billion through 2024 to enhance its global vaccine manufacturing capabilities.
Merck (NYSE: MRK) announced the fifth round of grants in its Merck for Mothers Global Grants program, aimed at reducing maternal mortality in critical regions. Launched in 2011, this initiative has supported over 60 projects globally, benefiting 3.5 million women and training 60,000 healthcare workers. The current grantees will implement high-impact activities across Asia Pacific, Europe, Africa, the Middle East, and Latin America, promoting health equity and improving maternal health services.
Merck (NYSE: MRK) announced the voluntary withdrawal of the U.S. indication for KEYTRUDA (pembrolizumab) in treating metastatic small cell lung cancer (SCLC) post-chemotherapy. This decision, made in consultation with the FDA, is part of a broader industry review of accelerated approvals. The withdrawal does not impact other KEYTRUDA indications. The accelerated approval, granted in June 2019, was based on tumor response data, but the confirmatory trial did not show statistical significance in overall survival. Merck is notifying healthcare providers and suggests patients discuss treatment options.
Merck (NYSE: MRK) announced that the FDA has accepted its New Drug Application (NDA) for gefapixant, a selective P2X3 receptor antagonist, aimed at treating refractory chronic cough (RCC) and unexplained chronic cough (UCC) in adults. The FDA has set a target action date of December 21, 2021. This application is based on results from the COUGH-1 and COUGH-2 clinical trials, which include over 2,000 patients. If approved, gefapixant would become the first medication specifically indicated for these conditions, addressing a significant unmet medical need.
Merck Animal Health, a division of Merck & Co. (NYSE: MRK), has completed the acquisition of Poultry Sense Ltd., an innovator in poultry health monitoring solutions. This acquisition aims to enhance Merck's technology portfolio to improve animal well-being and productivity in the poultry industry. Poultry Sense's technology allows real-time tracking of health indicators through wireless sensors, facilitating earlier illness detection and better farm management. Specific financial terms were not disclosed. This move aligns with Merck's strategy to expand its digital capabilities in animal health.
